batroxobin
ApprovedSmall molecule
batroxobin is one of 42 small molecule programs targeting Venous thrombosis. It is currently in Approved.
1
Indications
1
Total Trials
1
Active Trials
41
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
50 competitors in Venous Thrombosis
#DrugCompanyPhaseTrials
1Eliquis
Bristol-Myers SquibbApproved
Bayer Aspirin
BayerApproved
Arixtra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Lovenox
SanofiPhase 3
Innohep
Alnylam PharmaceuticalsPhase 3
Xarelto
WWim Janssens
Phase 3
Coumadin
AAbbott
Phase 3
Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Phase 3
Anticoagulation
HHospital Álvaro Cunqueiro
Approved
Acenocoumarol
RocheApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for batroxobin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- XXuanwu Hospital, Beijing